Keyword: Fred Hutchinson Cancer Research Center
Biotech developments over the past week include promising data from a human trial of male contraception and a new strategy to protect against malaria.
Takeda has added another early-stage research partnership as it reboots its R&D operations, this time teaming with two Seattle-based academic centers.
The past week saw news of a partnership aimed at improving cancer discovery, a technique for reversing heart damage and a new cancer-killing cell.
Fred Hutchinson scientists have identified biomarkers associated with dangerous side effects possible in cancer patients treated with CAR-T cells.
The agreement gives the Fortress Biotech offshoot a phase 1/2-ready cell therapy to advance alongside its existing clutch of CAR-Ts.
Fred Hutch scientists have created nanoparticles that could address shortcomings associated with CAR-T cancer treatments.
The collaborators hope to learn about the role Sigma1 plays in disease and assess the activity of Context’s inhibitors of the protein.
Juno Therapeutics has halted development of its lead CAR-T therapy months after patient deaths hindered the odds of success.
One big challenge of using T cells to treat cancer is that each infusion contains thousands of different varieties of the cells, some of which are much more effective at killing cancer than others are. So scientists at the Fred Hutchinson Cancer Research Center in Seattle have come up with a new way to find the cells that are most likely to lead the attack against tumors.
